


## Regorafenib

<http://cn.lumiprobe.com/p/regorafenib-755037-03-7>

It is a broad-spectrum multi-kinase inhibitor that blocks several protein kinases involved in key processes of tumor growth. The targets of this agent include KIT, RET, RAF-1, and BRAF kinases (including the mutant BRAF V600E form). It also affects the tumor microenvironment by suppressing PDGFR and FGFR, inhibits angiogenesis by suppressing VEGF receptors (VEGFR1, -2, -3) and TIE2, and can modulate immunity through CSF1R inhibition. Regorafenib is used for the treatment of various solid tumors: in metastatic colorectal cancer patients after prior chemotherapy, in unresectable or metastatic gastrointestinal stromal tumors (GIST) after progression on imatinib and sunitinib, and in hepatocellular carcinoma patients previously treated with sorafenib. In preclinical research, regorafenib is employed to study mechanisms of drug resistance, evaluate synergistic effects in combination with immune checkpoint inhibitors (e.g., in microsatellite-stable colorectal cancer), as well as to investigate the tumor microenvironment and search for predictive biomarkers of therapy response.

This product is intended for research use only.



外观:

分子量: 482.82

CAS 编号: 755037-03-7

分子式: C<sub>21</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>3</sub>

溶解度:

质量控制: NMR <sup>1</sup>H 和 HPLC-MS (98+%)

储存条件:

法律声明: 仅限研究用途, 我们不向患者销售, 不可用于医疗目的。